Here are the 8-K filings from Starling Oncology, Inc. (STLN) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
An 8-K covers material events a company has to report between its quarterly reports, so if you follow STLN and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full STLN filings page.
Starling Oncology, Inc. reported third-quarter 2026 revenue of $169.767 million, up 24% year over year, and Adjusted EBITDA of $3.394 million versus a $3.459 million loss a year earlier. Net loss was $15.748 million, compared with $16.504 million. Specialty Pharmacy revenue increased 44%; capitated revenue increased 40%, and the segment’s gross margin was 24%.
For the nine months ended September 30, 2026, operating cash flow was $19.867 million, compared with $27.820 million used a year earlier; Free Cash Flow was $20.223 million versus $26.924 million used. Updated full-year 2026 guidance is revenue of $650 million to $660 million, gross profit of $107 million to $110 million, Adjusted EBITDA of $4 million to $6 million, and Free Cash Flow of $5 million to $10 million. Previous ranges were $650 million to $670 million, $105 million to $110 million, $2 million to $7 million, and $5 million to $15 million, respectively.
For the fourth quarter, Starling expects Adjusted EBITDA of $3 million to $5 million as it onboards and ramps Florida delegated lives. It expects approximately $110 million in capitated revenue for 2026 and a Medical Loss Ratio of 85% to 90% in 2027 with onboarding of new lives.
Starling Oncology, Inc. (STLN) reported a board-level change. On September 1, 2026, director Brad Hively notified the company that he will not stand for re-election to the Board at the 2027 annual meeting of stockholders. He is expected to remain a director until that meeting but, effective immediately, no longer serves as Vice Chairman of the Board or as a member of the Compliance Committee or any other board committees. The company states that his decision is not due to any disagreement regarding its operations, policies, or practices.
Starling Oncology, Inc. (STLN) disclosed that its wholly owned subsidiary, Starling Oncology Management, LLC, entered into a new Revolving Loan Agreement with Gemino Healthcare Finance, LLC d/b/a SLR Healthcare ABL. The facility provides a revolving line of credit with an aggregate principal commitment of up to $25 million, intended to offer additional financial flexibility for working capital and general corporate purposes.
The revolver is secured by a first-priority security interest in substantially all of the subsidiary’s collateral and matures on August 20, 2029. Borrowing availability is governed by a borrowing base tied to certain accounts receivable and related lockbox arrangements with supported professional corporations. Loans bear interest at Term SOFR plus 3.95%, where Term SOFR is the greater of a three‑month forward-looking SOFR rate and 2.00% per annum, with a 5.00% default-rate premium if an event of default occurs.
Starling Oncology must also pay monthly collateral monitoring and unused line fees, a minimum use fee tied to a $5 million minimum balance, and a termination fee of 3.00%, 2.00%, or 1.00% of the commitment depending on when the facility is terminated. Covenants include customary limits on additional debt, liens, and distributions, and require Maximum Loan Turn Days not to exceed 35 days on a rolling three‑month basis each fiscal quarter beginning with the quarter ending December 31, 2026.